Spyre Therapeutics Financials
| SYRE Stock | 18.17 0.02 0.11% |
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Debt Equity Ratio | 0.43 | 0.41 |
|
| |||||
| Current Ratio | 6.62 | 11.2555 |
|
|
The essential information of the day-to-day investment outlook for Spyre Therapeutics includes many different criteria found on its balance sheet. An individual investor should monitor Spyre Therapeutics' cash flow, debt, and profitability to accurately make informed decisions on whether to invest in Spyre Therapeutics.
Net Income |
|
Spyre | Select Account or Indicator |
Please note, the presentation of Spyre Therapeutics' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Spyre Therapeutics' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Spyre Therapeutics' management manipulating its earnings.
Spyre Therapeutics Stock Summary
Spyre Therapeutics competes with Aris Water, CenterPoint Energy, Enel Chile, BBB Foods, and Paranovus Entertainment. Spyre Therapeutics is entity of United States. It is traded as Stock on NASDAQ exchange.Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Instrument | USA Stock View All |
| Exchange | NASDAQ Exchange |
| CUSIP | 00773J103 00773J202 |
| Location | Texas; U.S.A |
| Business Address | 221 Crescent Street, |
| Sector | Biotechnology |
| Industry | Health Care |
| Benchmark | Dow Jones Industrial |
| Website | www.spyre.com |
| Phone | 617 651 5940 |
Spyre Therapeutics Key Financial Ratios
| Return On Equity | -0.59 | ||||
| Price To Sales | 650.22 X | ||||
| Revenue | 886 K | ||||
| Gross Profit | (162.79 M) | ||||
| EBITDA | (208.57 M) |
Spyre Therapeutics Key Balance Sheet Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Total Assets | 161.6M | 109.9M | 71.1M | 341.9M | 608.5M | 638.9M | |
| Other Current Liab | 464K | 14.0M | 12.8M | 31.1M | 53.4M | 56.1M | |
| Net Debt | (84.6M) | (10.1M) | (30.2M) | (104.3M) | (89.4M) | (85.0M) | |
| Retained Earnings | (276.0M) | (341.8M) | (425.6M) | (764.4M) | (972.4M) | (923.8M) | |
| Accounts Payable | 2.3M | 3.3M | 677K | 896K | 666K | 632.7K | |
| Cash | 90.1M | 15.1M | 34.9M | 188.9M | 89.4M | 63.6M | |
| Other Current Assets | 3.5M | 4.9M | 6.2M | 2.3M | 5.4M | 3.7M | |
| Total Liab | 21.8M | 26.0M | 20.8M | 157.8M | 90.7M | 95.2M | |
| Total Current Assets | 149.8M | 98.9M | 62.3M | 341.5M | 608.5M | 638.9M | |
| Net Invested Capital | 139.8M | 83.9M | 50.3M | (911K) | 362.0M | 380.1M | |
| Net Working Capital | 133.3M | 78.7M | 47.6M | 309.6M | 554.4M | 582.1M |
Spyre Therapeutics Key Income Statement Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Gross Profit | (1.6M) | 16.7M | 365K | (78K) | (70.2K) | (66.7K) | |
| Operating Income | (81.5M) | (65.6M) | (84.8M) | (242.3M) | (208.6M) | (198.1M) | |
| Ebit | (80.9M) | (65.7M) | (85.2M) | (243.0M) | (128.8M) | (135.2M) | |
| Research Development | 59.6M | 57.1M | 58.6M | 89.5M | 162.8M | 170.9M | |
| Ebitda | (79.3M) | (63.7M) | (83.2M) | (242.3M) | (208.6M) | (198.1M) | |
| Income Before Tax | (80.9M) | (65.7M) | (84.0M) | (338.8M) | (208.0M) | (197.6M) | |
| Net Income | (80.9M) | (65.8M) | (83.8M) | (338.8M) | (208.0M) | (197.6M) | |
| Net Interest Income | 593K | 111K | 837K | 6.1M | 21.3M | 22.4M | |
| Interest Income | 593K | 111K | 837K | 6.1M | 21.3M | 22.4M | |
| Cost Of Revenue | 1.6M | 2.0M | 2.0M | 964K | 867.6K | 1.1M |
Spyre Therapeutics Key Cash Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Change In Cash | 71.2M | (75.0M) | 19.4M | 152.8M | (99.8M) | (94.8M) | |
| Free Cash Flow | (80.1M) | (54.3M) | (80.2M) | (99.9M) | (157.4M) | (149.5M) | |
| Depreciation | 996K | 1.6M | 1.6M | 744K | (11.4M) | (10.8M) | |
| Other Non Cash Items | 619K | 90K | 823K | 217.7M | 17.2M | 30.3M | |
| Capital Expenditures | 422K | 1.5M | 4.3M | 573K | 38K | 0.0 | |
| Net Income | (80.9M) | (65.8M) | (83.8M) | (338.8M) | (208.0M) | (197.6M) | |
| End Period Cash Flow | 91.9M | 17.0M | 36.4M | 189.2M | 89.4M | 64.3M | |
| Investments | (7.6M) | (22.6M) | 57.0M | (108.4M) | (353.3M) | (335.6M) |
Spyre Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Spyre Therapeutics's current stock value. Our valuation model uses many indicators to compare Spyre Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Spyre Therapeutics competition to find correlations between indicators driving Spyre Therapeutics's intrinsic value. More Info.Spyre Therapeutics is currently regarded as top stock in return on equity category among its peers. It also is currently regarded as top stock in return on asset category among its peers . At present, Spyre Therapeutics' Return On Equity is projected to slightly grow based on the last few years of reporting. Comparative valuation analysis is a catch-all technique that is used if you cannot value Spyre Therapeutics by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Spyre Therapeutics Systematic Risk
Spyre Therapeutics' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Spyre Therapeutics volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was twenty with a total number of output elements of fourty-one. The Beta measures systematic risk based on how returns on Spyre Therapeutics correlated with the market. If Beta is less than 0 Spyre Therapeutics generally moves in the opposite direction as compared to the market. If Spyre Therapeutics Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Spyre Therapeutics is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Spyre Therapeutics is generally in the same direction as the market. If Beta > 1 Spyre Therapeutics moves generally in the same direction as, but more than the movement of the benchmark.
Spyre Therapeutics Thematic Clasifications
Spyre Therapeutics is part of several thematic ideas from Health Management to Management. If you are a theme-oriented, socially responsible, and at the same time, a result-driven investor, you can align your investing habits with your values without jeopardizing your expectations about returns. You can easily create an optimal portfolio of stocks, ETFs, funds, or cryptocurrencies based on a specific theme of your liking. Get More Thematic IdeasToday, most investors in Spyre Therapeutics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Spyre Therapeutics' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Spyre Therapeutics growth as a starting point in their analysis.
Price Earnings To Growth Ratio |
|
Spyre Therapeutics March 22, 2025 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Spyre Therapeutics help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Spyre Therapeutics. We use our internally-developed statistical techniques to arrive at the intrinsic value of Spyre Therapeutics based on widely used predictive technical indicators. In general, we focus on analyzing Spyre Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Spyre Therapeutics's daily price indicators and compare them against related drivers.
| Information Ratio | (0.08) | |||
| Maximum Drawdown | 16.98 | |||
| Value At Risk | (6.49) | |||
| Potential Upside | 5.29 |
Complementary Tools for Spyre Stock analysis
When running Spyre Therapeutics' price analysis, check to measure Spyre Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Spyre Therapeutics is operating at the current time. Most of Spyre Therapeutics' value examination focuses on studying past and present price action to predict the probability of Spyre Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Spyre Therapeutics' price. Additionally, you may evaluate how the addition of Spyre Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal |